The Journal of
Clinical Psychiatry

Depression (MDD)

Letter to the Editor November 15, 2003

Reply to Amitriptyline: Dual-Action Antidepressant?

Michael E. Thase, MD

J Clin Psychiatry 2003;64(11):1391-1392

Article Abstract

Letter to the Editor

Reply to Amitriptyline: Dual-Action Antidepressant?

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 86 • 2025 • Number 1

Read the Current Issue

Brief Report

Sex Differences in PTSD among US Military Veterans

Commentary

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Clinical and Practical Psychopharmacology

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Commentary

Evolving Care and Research Priorities in ADHD

Original Research

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Systematic Review

Efficacy and Safety of Memantine for Children and Adults with ADHD

View current Issue

Related Articles

Is Bariatric Surgery an Antidepressant?

Letter to the Editor

Is Bariatric Surgery an Antidepressant?

October 29, 2024

The effect of bariatric surgery on mood disorders is uncertain. Read on to find out more.

Ahmed Naguy

What Clinicians Need to Know About Geriatric Depression

Letter to the Editor

What Clinicians Need to Know About Geriatric Depression

May 16, 2024

The authors discuss what clinicians should be aware of when caring for elderly patients with depression.

Ahmed Naguy , Soliman Al-Khadhari

Intravenous Ketamine vs Intranasal Esketamine for TRD

Letter to the Editor

Intravenous Ketamine vs Intranasal Esketamine for TRD

February 13, 2024

Dr Mansuri and colleagues compare the pros and cons of IV ketamine and intranasal esketamine for treatment-resistant depression.

Zeeshan Mansuri , Bhumika Shah , Garima Yadav , et al